Supernus Pharmaceuticals, Inc. (SUPN) — Fair Value Analysis

Base-case fair value (P50): $42.87 · Current price: $44.40 · Verdict: Fairly Valued

The Verdict on SUPN

Our Monte Carlo simulations indicate SUPERNUS PHARMACEUTICALS INC (SUPN) is currently Fairly Valued. With the stock trading at $44.40, our median fair value (P50) estimate is $42.87. This suggests a -3.4% difference from the current market price, placing SUPN squarely within its fair value range based on thousands of forward-looking scenarios. The verdict of Fairly Valued reflects a balance between potential growth drivers and inherent risks, as assessed through our rigorous quantitative framework. Investors should note this slight discrepancy between the $44.40 and $42.87 suggests the market is largely aligned with our fundamental valuation.

How SUPN stacks up against peers

SUPN's operational and financial health is categorized as average within its sector. This average quality tier implies that while SUPN is not a market leader in terms of fundamental strength, it also doesn't present significant immediate red flags compared to its peers. The current market price of $44.40 relative to our $42.87 fair value suggests that the market is appropriately pricing in this average quality, without assigning a premium or a steep discount. While our Fairly Valued verdict is consistent with an average quality tier, deeper analysis of its competitive landscape would reveal specific strengths and weaknesses driving this assessment, considering the -3.4% differential.

What this means for investors

For investors considering SUPN, the Fairly Valued verdict, coupled with an average quality tier, implies that significant short-term alpha from a valuation perspective may be limited unless new catalysts emerge. The proximity of $44.40 to our $42.87 median fair value, with only a -3.4% variance, suggests that the current price reflects a reasonable consensus on SUPN's intrinsic worth. While some investors might seek more pronounced upside, the current valuation provides a solid basis for long-term holders. FairCurve's Monte Carlo analysis considers a broad spectrum of future economic and company-specific outcomes. To understand the full range of possibilities, including the bear and bull case scenarios and the probability of achieving significant upside from $44.40, sign up for a free FairCurve account.